BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsEarnings

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026

Related news

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

PHVSPharvaris2026-05-12 20:05 EST

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PTCTPTC Therapeutics, Inc.2026-05-07 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

CRISCuris2026-05-05 21:11 EST

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Stock data

Close
9.30 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States